4月2日 - **制药商Arcutis BiotherapeuticsARQT.O股价上涨12.9%至16.91美元
** 该公司称已同意暂时停止 (link) 与以色列 Padagis 公司的专利诉讼，因为后者试图生产 ARQT 的 Zoryve 的仿制药。
**Zoryve 用于治疗皮肤疾病，包括斑块型银屑病、脂溢性皮炎和特应性皮炎。
** 作为协议的一部分，Padagis将随时向Arcutis通报其与FDA就Zoryve仿制药进行沟通的最新情况。
** Zoryve的专利保护期至少到2037年
** 包括本交易日的走势在内，ARQT股价今年以来上涨了19.4%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.